Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-epigallocatechin 3-gallate | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of G2E3 mRNA | CTD | PMID:22079256 | (1->4)-beta-D-glucan | multiple interactions | EXP | | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of G2E3 mRNA | CTD | PMID:36331819 | 1,2-dimethylhydrazine | decreases expression | EXP | | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of G2E3 mRNA | CTD | PMID:22206623 | 17beta-estradiol | increases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Estradiol results in increased expression of G2E3 mRNA | CTD | PMID:19167446 | 2,2',4,4',5,5'-hexachlorobiphenyl | multiple interactions | EXP | | 6480464 | [2 more ... | CTD | PMID:25510870 | 2,2',5,5'-tetrachlorobiphenyl | multiple interactions | EXP | | 6480464 | [2 more ... | CTD | PMID:25510870 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | G2E3 (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin affects the expression of G2E3 mRNA | CTD | PMID:22298810 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of G2E3 mRNA | CTD | PMID:32109520 and PMID:33387578 | 4-hydroxyphenyl retinamide | increases expression | EXP | | 6480464 | Fenretinide results in increased expression of G2E3 mRNA | CTD | PMID:28973697 | acetamide | increases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | acetamide results in increased expression of G2E3 mRNA | CTD | PMID:31881176 | acrylamide | increases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | Acrylamide results in increased expression of G2E3 mRNA | CTD | PMID:28959563 | aflatoxin B1 | increases expression | EXP | | 6480464 | Aflatoxin B1 results in increased expression of G2E3 mRNA | CTD | PMID:19770486 | aflatoxin B1 | decreases methylation | ISO | G2E3 (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased methylation of G2E3 gene | CTD | PMID:27153756 | aflatoxin M1 | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Aflatoxin M1 results in decreased expression of G2E3 mRNA | CTD | PMID:30928695 | all-trans-retinoic acid | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of G2E3 mRNA | CTD | PMID:21934132 | antirheumatic drug | increases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Antirheumatic Agents results in increased expression of G2E3 mRNA | CTD | PMID:24449571 | aristolochic acid A | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | aristolochic acid I results in decreased expression of G2E3 mRNA | CTD | PMID:33212167 | arsenite(3-) | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | arsenite inhibits the reaction [G3BP1 protein binds to G2E3 mRNA] | CTD | PMID:32406909 | atrazine | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Atrazine results in decreased expression of G2E3 mRNA | CTD | PMID:22378314 | benzo[a]pyrene | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased expression of G2E3 mRNA | CTD | PMID:21632981 and PMID:22316170 | benzo[a]pyrene | decreases methylation | ISO | G2E3 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased methylation of G2E3 promoter | CTD | PMID:27901495 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:20018196 and PMID:20382639 | bisphenol A | affects expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | bisphenol A affects the expression of G2E3 mRNA | CTD | PMID:25181051 | bisphenol A | increases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of G2E3 mRNA | CTD | PMID:32145629 and PMID:34947998 | butanal | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | butyraldehyde results in decreased expression of G2E3 mRNA | CTD | PMID:26079696 | cadmium atom | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of G2E3 mRNA | CTD | PMID:35301059 | cadmium dichloride | increases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Cadmium Chloride results in increased expression of G2E3 mRNA | CTD | PMID:26472689 | cadmium dichloride | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of G2E3 mRNA | CTD | PMID:35301059 | calcitriol | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Calcitriol results in decreased expression of G2E3 mRNA | CTD | PMID:21592394 | calcitriol | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of G2E3 mRNA | CTD | PMID:21592394 | carbamazepine | affects expression | ISO | G2E3 (Homo sapiens) | 6480464 | Carbamazepine affects the expression of G2E3 mRNA | CTD | PMID:25979313 | carbon nanotube | increases expression | EXP | | 6480464 | Nanotubes and Carbon results in increased expression of G2E3 mRNA | CTD | PMID:25554681 | cisplatin | increases expression | EXP | | 6480464 | Cisplatin results in increased expression of G2E3 mRNA | CTD | PMID:21151649 | cisplatin | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Cisplatin results in decreased expression of G2E3 mRNA | CTD | PMID:27392435 and PMID:27594783 | cisplatin | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of G2E3 mRNA | CTD | PMID:27392435 | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of G2E3 mRNA | CTD | PMID:25270620 | copper atom | increases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | Copper deficiency results in increased expression of G2E3 mRNA | CTD | PMID:26033743 | copper(0) | increases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | Copper deficiency results in increased expression of G2E3 mRNA | CTD | PMID:26033743 | coumestrol | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of G2E3 mRNA | CTD | PMID:19167446 | coumestrol | increases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Coumestrol results in increased expression of G2E3 mRNA | CTD | PMID:19167446 | cyclosporin A | increases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of G2E3 mRNA | CTD | PMID:25562108 | dicrotophos | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | dicrotophos results in decreased expression of G2E3 mRNA | CTD | PMID:28302478 | diethylstilbestrol | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Diethylstilbestrol results in decreased expression of G2E3 mRNA | CTD | PMID:36621641 | dorsomorphin | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of G2E3 mRNA | CTD | PMID:29803840 | doxorubicin | multiple interactions | EXP | | 6480464 | [Doxorubicin co-treated with Folic Acid] results in increased expression of G2E3 mRNA | CTD | PMID:28608983 | Enterolactone | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of G2E3 mRNA | CTD | PMID:19167446 | folic acid | multiple interactions | EXP | | 6480464 | [Doxorubicin co-treated with Folic Acid] results in increased expression of G2E3 mRNA | CTD | PMID:28608983 | formaldehyde | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Formaldehyde results in decreased expression of G2E3 mRNA | CTD | PMID:23649840 | glycidol | increases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | glycidol results in increased expression of G2E3 mRNA | CTD | PMID:24915197 | gold atom | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Gold results in decreased expression of G2E3 mRNA | CTD | PMID:25523186 | gold(0) | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Gold results in decreased expression of G2E3 mRNA | CTD | PMID:25523186 | hydrogen peroxide | increases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Hydrogen Peroxide results in increased expression of G2E3 mRNA | CTD | PMID:18951874 | inulin | multiple interactions | EXP | | 6480464 | [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of G2E3 mRNA | CTD | PMID:36331819 | irinotecan | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Irinotecan analog results in decreased expression of G2E3 mRNA | CTD | PMID:18927307 | menadione | decreases expression | EXP | | 6480464 | Vitamin K 3 results in decreased expression of G2E3 mRNA | CTD | PMID:25270620 | ochratoxin A | increases expression | ISO | G2E3 (Homo sapiens) | 6480464 | ochratoxin A results in increased expression of G2E3 mRNA | CTD | PMID:30559759 | oxaliplatin | decreases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | oxaliplatin results in decreased expression of G2E3 mRNA | CTD | PMID:25729387 | oxaliplatin | multiple interactions | ISO | G2e3 (Rattus norvegicus) | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of G2E3 mRNA | CTD | PMID:25729387 | ozone | multiple interactions | EXP | | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of G2E3 mRNA and [Air Pollutants results in increased abundance of Ozone] which results in increased expression of G2E3 mRNA | CTD | PMID:34911549 | paracetamol | increases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Acetaminophen results in increased expression of G2E3 mRNA | CTD | PMID:22230336 | paracetamol | decreases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | Acetaminophen results in decreased expression of G2E3 mRNA | CTD | PMID:33387578 | PCB138 | multiple interactions | EXP | | 6480464 | [2 more ... | CTD | PMID:25510870 | perfluorooctane-1-sulfonic acid | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | perfluorooctane sulfonic acid results in decreased expression of G2E3 mRNA | CTD | PMID:27153767 | perfluorooctane-1-sulfonic acid | multiple interactions | EXP | | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of G2E3 mRNA and [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of G2E3 mRNA | CTD | PMID:36331819 | phenobarbital | decreases expression | EXP | | 6480464 | Phenobarbital results in decreased expression of G2E3 mRNA | CTD | PMID:23091169 | phenylmercury acetate | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in decreased expression of G2E3 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of G2E3 mRNA | CTD | PMID:27188386 | potassium chromate | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of G2E3 mRNA | CTD | PMID:22079256 | potassium chromate | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | potassium chromate(VI) results in decreased expression of G2E3 mRNA | CTD | PMID:22079256 | quercetin | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Quercetin results in decreased expression of G2E3 mRNA | CTD | PMID:21632981 | resveratrol | increases expression | ISO | G2E3 (Homo sapiens) | 6480464 | resveratrol results in increased expression of G2E3 mRNA | CTD | PMID:19167446 | SB 431542 | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | succimer | multiple interactions | EXP | | 6480464 | [Succimer binds to Magnetite Nanoparticles] which results in decreased expression of G2E3 mRNA and [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of G2E3 mRNA | CTD | PMID:21641980 and PMID:26378955 | sunitinib | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of G2E3 mRNA | CTD | PMID:31533062 | testosterone | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of G2E3 mRNA | CTD | PMID:21592394 | testosterone | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Testosterone results in decreased expression of G2E3 mRNA | CTD | PMID:21592394 | tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of G2E3 mRNA | CTD | PMID:31919559 | thioacetamide | increases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | Thioacetamide results in increased expression of G2E3 mRNA | CTD | PMID:23411599 and PMID:34492290 | topotecan | decreases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | Topotecan results in decreased expression of G2E3 mRNA | CTD | PMID:25729387 | topotecan | multiple interactions | ISO | G2e3 (Rattus norvegicus) | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of G2E3 mRNA | CTD | PMID:25729387 | trichloroethene | decreases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | Trichloroethylene results in decreased expression of G2E3 mRNA | CTD | PMID:33387578 | trichostatin A | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of G2E3 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of G2E3 mRNA | CTD | PMID:27188386 | trimellitic anhydride | increases expression | EXP | | 6480464 | trimellitic anhydride results in increased expression of G2E3 mRNA | CTD | PMID:19042947 | trovafloxacin | decreases expression | EXP | | 6480464 | trovafloxacin results in decreased expression of G2E3 mRNA | CTD | PMID:35537566 | tungsten | increases expression | EXP | | 6480464 | Tungsten results in increased expression of G2E3 mRNA | CTD | PMID:30912803 | valproic acid | increases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of G2E3 mRNA | CTD | PMID:29154799 | valproic acid | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of G2E3 mRNA | CTD | PMID:23179753 and PMID:27188386 | vinclozolin | increases expression | ISO | G2e3 (Rattus norvegicus) | 6480464 | vinclozolin results in increased expression of G2E3 mRNA | CTD | PMID:23034163 | vorinostat | decreases expression | ISO | G2E3 (Homo sapiens) | 6480464 | vorinostat results in decreased expression of G2E3 mRNA | CTD | PMID:27188386 | zinc atom | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of G2E3 mRNA | CTD | PMID:18593933 | zinc(0) | multiple interactions | ISO | G2E3 (Homo sapiens) | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of G2E3 mRNA | CTD | PMID:18593933 | |